By Ada Hui
Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from its Phase 1/1b clinical trial of CPI-818, an ITK inhibitor it is developing to treat solid and hematological cancers.
The interim trial data taken as of mid-May showed that out of 30 patients with relapsed T-cell lymphoma who were dosed with 200 mg of CPI-818 twice a day, only three patients experienced complete responses and three patients experienced partial responses.
One partial response saw continued tumor regression. One complete response and the other two partial responses remained on therapy.
According to the company, CPI-818 increases tumor-killing T cells by modulating T cell differentiation and reducing T cell exhaustion.
Corvus also said it is testing CPI-818 in B cell lymphoma and colon cancer models and that it is planning to meet with the U.S. Food and Drug Administration in the third quarter to discuss potentially registering a Phase 3 clinical trial to evaluate CPI-818 for the treatment of T-cell lymphoma.
Write to Ada Hui at [email protected]
Read the full article here
